Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,079 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00553410 | Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer(SOLE) | completed | Phase 3 | 4,884 | ETOP IBCSG Partners FoundationNETWORK | 20 | Sep 1, 2026 | clinicaltrials |
| NCT05645536 | Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study | enrolling by invitation | Phase 3 | 250 | Tolmar Inc.INDUSTRY |
| 6 |
| Sep 1, 2026 |
| clinicaltrials |
| NCT04538664 | A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions(PAPILLON) | active not recruiting | Phase 3 | 308 | Janssen Research & Development, LLCINDUSTRY | 26 | Aug 31, 2026 | clinicaltrials |
| NCT07486518 | A Multicentre Observational Cross-Sectional Study of The Gastric Precancerous Epithelial Pathway Using High-Definition Endoscopy And Histopathology In India(IND-PREP) | recruiting | — | 4,000 | Asian Institute of Gastroenterology, IndiaOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04971226 | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | active not recruiting | Phase 3 | 405 | Novartis PharmaceuticalsINDUSTRY | 29 | Aug 28, 2026 | clinicaltrials |
| NCT05211895 | A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC(PACIFIC-8) | active not recruiting | Phase 3 | 791 | AstraZenecaINDUSTRY | 28 | Aug 28, 2026 | clinicaltrials |
| NCT03875235 | Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)(TOPAZ-1) | active not recruiting | Phase 3 | 810 | AstraZenecaINDUSTRY | 17 | Aug 26, 2026 | clinicaltrials |
| NCT05456191 | A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)(ASC4START) | active not recruiting | Phase 3 | 568 | Novartis PharmaceuticalsINDUSTRY | 24 | Aug 26, 2026 | clinicaltrials |
| NCT06350097 | Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer(TROPION-Lung14) | recruiting | Phase 3 | 582 | AstraZenecaINDUSTRY | 19 | Aug 26, 2026 | clinicaltrials |
| NCT07611110 | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)(VECTRA-01) | recruiting | Phase 3 | 670 | AstraZenecaINDUSTRY | 20 | Aug 26, 2026 | clinicaltrials |
| NCT03067181 | Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | recruiting | Phase 3 | 1,780 | Children's Oncology GroupNETWORK | 9 | Aug 25, 2026 | clinicaltrials |
| NCT06079671 | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)(eVOLVECervical) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 19 | Aug 25, 2026 | clinicaltrials |
| NCT07669467 | Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer(NuvastaticTM) | recruiting | Phase 3 | 250 | Natureceuticals Sdn BhdINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07669519 | Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy(NuvastaticTM) | recruiting | Phase 3 | 180 | Natureceuticals Sdn BhdINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07680790 | Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) | not yet recruiting | Phase 3 | 850 | Bristol-Myers SquibbINDUSTRY | 16 | Aug 24, 2026 | clinicaltrials |
| NCT06499285 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | recruiting | Phase 3 | 225 | TakedaINDUSTRY | 26 | Aug 21, 2026 | clinicaltrials |
| NCT06862219 | A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer | recruiting | Phase 4 | 100 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT02386800 | CINC424A2X01B Rollover Protocol | active not recruiting | Phase 4 | 279 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 20, 2026 | clinicaltrials |
| NCT03682068 | Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer(NILE) | active not recruiting | Phase 3 | 1,246 | AstraZenecaINDUSTRY | 22 | Aug 20, 2026 | clinicaltrials |
| NCT05817110 | Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.(CREATE) | active not recruiting | — | 712 | AstraZenecaINDUSTRY | 5 | Aug 20, 2026 | clinicaltrials |
| NCT05774951 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy(CAMBRIA-1) | recruiting | Phase 3 | 4,300 | AstraZenecaINDUSTRY | 39 | Aug 19, 2026 | clinicaltrials |
| NCT06467357 | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer(DESTINY-BTC01) | recruiting | Phase 3 | 620 | AstraZenecaINDUSTRY | 27 | Aug 19, 2026 | clinicaltrials |
| NCT04862663 | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)(CAPItello-292) | active not recruiting | Phase 3 | 893 | AstraZenecaINDUSTRY | 23 | Aug 17, 2026 | clinicaltrials |
| NCT06492486 | Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow(GLADIATOR) | recruiting | Phase 2 | 60 | Tata Memorial CentreOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03847428 | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment(EMERALD-2) | active not recruiting | Phase 3 | 908 | AstraZenecaINDUSTRY | 24 | Aug 14, 2026 | clinicaltrials |
| NCT03782207 | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice(IMreal) | completed | — | 2,756 | Hoffmann-La RocheINDUSTRY | 30 | Aug 13, 2026 | clinicaltrials |
| NCT04603807 | A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases | active not recruiting | Phase 3 | 217 | Hoffmann-La RocheINDUSTRY | 18 | Aug 13, 2026 | clinicaltrials |
| NCT07459543 | A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India | not yet recruiting | Phase 4 | 40 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05113251 | Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | active not recruiting | Phase 3 | 927 | AstraZenecaINDUSTRY | 18 | Aug 11, 2026 | clinicaltrials |
| NCT05303532 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab(ROSY-D) | enrolling by invitation | Phase 3 | 214 | AstraZenecaINDUSTRY | 31 | Aug 11, 2026 | clinicaltrials |
| NCT05952557 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)(CAMBRIA-2) | active not recruiting | Phase 3 | 5,511 | AstraZenecaINDUSTRY | 44 | Aug 10, 2026 | clinicaltrials |
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | recruiting | Phase 2 / Phase 3 | 600 | Bristol-Myers SquibbINDUSTRY | 28 | Aug 10, 2026 | clinicaltrials |
| NCT04269200 | Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer(DUO-E) | active not recruiting | Phase 3 | 805 | AstraZenecaINDUSTRY | 22 | Aug 7, 2026 | clinicaltrials |
| NCT02542293 | Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)(NEPTUNE) | active not recruiting | Phase 3 | 953 | AstraZenecaINDUSTRY | 29 | Aug 6, 2026 | clinicaltrials |
| NCT03706690 | A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients(PACIFIC-5) | active not recruiting | Phase 3 | 407 | AstraZenecaINDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT03521154 | A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)(LAURA) | active not recruiting | Phase 3 | 216 | AstraZenecaINDUSTRY | 17 | Aug 4, 2026 | clinicaltrials |
| NCT07717307 | Study Comparing Limited and Extensive Neck Surgery in Oral Cancer Patients With Neck Spread(ExtentN1) | recruiting | N/A | 80 | Kolhapur Cancer Centre - Cancer Centers of AmericaOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07726199 | Study Comparing Different Neck Treatment Approaches in Patients With Oral Cancer Without Visible Neck Spread(ExtentN0) | recruiting | N/A | 267 | Kolhapur Cancer Centre - Cancer Centers of AmericaOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07209917 | Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India(SAKHI) | recruiting | N/A | 348 | University of California, IrvineOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03363373 | Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow | active not recruiting | Phase 2 | 122 | Y-mAbs TherapeuticsINDUSTRY | 9 | Jul 30, 2026 | clinicaltrials |
| NCT04606771 | A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC(CoC) | active not recruiting | Phase 2 | 30 | AstraZenecaINDUSTRY | 6 | Jul 30, 2026 | clinicaltrials |
| NCT04784715 | Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | active not recruiting | Phase 3 | 1,157 | AstraZenecaINDUSTRY | 27 | Jul 30, 2026 | clinicaltrials |
| NCT06120491 | Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents(EvoPAR-PR01) | active not recruiting | Phase 3 | 1,898 | AstraZenecaINDUSTRY | 24 | Jul 29, 2026 | clinicaltrials |
| NCT05984277 | A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.(eVOLVE-Lung02) | active not recruiting | Phase 3 | 895 | AstraZenecaINDUSTRY | 25 | Jul 28, 2026 | clinicaltrials |
| NCT07042100 | A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 177 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 3 | Jul 28, 2026 | clinicaltrials |
| NCT03298451 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma(HIMALAYA) | active not recruiting | Phase 3 | 1,324 | AstraZenecaINDUSTRY | 17 | Jul 27, 2026 | clinicaltrials |
| NCT07709195 | Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant(ChROMME-TBI) | recruiting | Phase 2 | 17 | Tata Memorial CentreOTHER | 1 | Jul 27, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials